cas 920509-28-0|| where to buy 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one

製品名:6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one

IUPAC Name:6-(4-amino-2,6-dichlorophenoxy)-4-(propan-2-yl)-2,3-dihydropyridazin-3-one

包装単位	有効在庫	価格（USD）
CM630981-250mg	in stock	ƈƈ
CM630981-1g	in stock	ǸƴŌ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 920509-28-0 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:920509-28-0; 分子式:C13H13Cl2N3O2; 融点:-; SMILESコード:CC(C)C1=CC(OC2=C(Cl)C=C(N)C=C2Cl)=NNC1=O; 密度:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Resmetirom; Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis.
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD).
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.

: ALG-055009; Aligos Therapeutics announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects. ALG-055009 demonstrated a favorable tolerability profile with no serious adverse events (SAEs), or clinical hyper/hypothyroidism. The majority of treatment emergent adverse events (TEAEs) were mild to moderate, with one discontinuation due to worsening insomnia in a subject with pre-existing insomnia.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.